Default Category
-
Cobertura del riesgo cambiario en EADS
Kester, W. Carl; Dessain, Vincent; Misztal, KarolCase HBS-218S03FinanceEn 2008, EADS, el grupo aeroespacial europeo que posee Airbus, se enfrentan a la decisión de la mejor manera de cubrir un desajuste importante y creciente entre sus ingresos en dólares y en euros sus costes de fabricación. En concreto, la empresa necesitaba para decidir si continuaría cobertura principalmente con contratos a plazo, pero en cantidades mucho más altas y a tasas cada vez más desfavorables, o para romper con la práctica anterior y co...Starting at €8.20
-
Reinventing Brainlab
Herzlinger, Regina E.; Dessain, Vincent; Misztal, KarolCase HBS-313069-EStrategyThe management of Germany's Brainlab AG, a leading provider of software-driven oncology and surgery solutions, needs to evaluate strategic options for proceeding without an exclusive hardware partner in its most profitable business segment.Starting at €8.20
-
Ilva Steel Taranto: Providing and Polluting (A)
Goldberg, Lena G.; Dessain, Vincent; Pesce, Ottavia; Misztal, KarolCase HBS-314045-ENearly 27,000 people depended on Ilva Steel Taranto, the largest steel-making plant in Europe, for their livelihoods, but the plant's pollution fouled the environment and increased the incidence of tumors, respiratory illnesses and deaths. In July 2012, faced with a court-ordered partial shut-down and a possibly unaffordable remediation plan, the company's newly appointed head must decide what to do next.Starting at €8.20
-
HgCapital and the Visma Transaction (A)
Gompers, Paul A.; Misztal, Karol; Van Gool, JorisCase HBS-214018-EFinanceThis case concerns the negotiations of a deal by HgCapital, a UK-based private equity firm, to buy Visma, ASA, a Norwegian software company. Visma has received an offer from Sage Group, a strategic acquirer. HgCapital must determine if it wants to bid and how to outbid a potential strategic acquirer. The case concerns bidding and negotiations strategies as well as deal structuring issues. In particular, the cross border nature of the investment, ...Starting at €8.20
-
HgCapital and the Visma Transaction (B-1): Nic Humphries
Gompers, Paul A.; Misztal, Karol; Van Gool, JorisCase HBS-214019-EFinanceStarting at €8.20
-
Poles apart on PZU (C)
Gino, Francesca; Dessain, Vincent; Misztal, Karol; Khayyat, MichaelCase HBS-912015-EAfter a decade-long dispute with the Polish State Treasury, in October 2009 the Dutch insurer Eureko agreed to exit PZU in exchange for compensation. Who was the biggest beneficiary of the settlement: Eureko, the Treasury, or PZU itself?Starting at €5.74
-
Reinventing Brainlab (B)
Herzlinger, Regina E.; Misztal, KarolCase HBS-314054-EStrategyThe management of Germany's Brainlab AG, a leading provider of software-driven oncology and surgery solutions, needs to evaluate strategic options for proceeding without an exclusive hardware partner in its most profitable business segment.Starting at €5.74
-
Oriflame S.A. (A)
Hawkins, David F.; Misztal, Karol; Beyersdorfer, DanielaCase HBS-111050-EAccounting and ControlA direct-selling cosmetics company involved in emerging markets exhibits significant foreign exchange risk exposure and profitability swings in the wake of the 2008 financial crisis. Students must review the company's use of derivative instruments and other hedging techniques to establish whether it pursues the right FX risk mitigation strategy.Starting at €8.20
-
Oriflame S.A. (C)
Hawkins, David F.; Misztal, KarolCase HBS-111052-EAccounting and ControlNotes from Oriflame's 2009 annual report relevant to the assessment of the monetary impact of Oriflame's FX risk management actions.Starting at €5.74
-
Novozymes: Cracking the Emerging Markets Code
Palepu, Krishna G.; Misztal, KarolCase HBS-112084-EIn 2011, the management of Novozymes, the industrial enzymes leader, reflected on the viability of their positioning in the fast growing, yet increasingly competitive Chinese market. Novozymes, a technological innovation pioneer, was prominent in China's premium enzyme markets, but felt pressure from local low-cost rivals in volume-driven, commoditized segments. How should Novozymes relate to local competitors? By competing on technological innov...Starting at €8.20